ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2022
Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation.
Article in European heart journal supplements : journal of the European Society of Cardiology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed.
- Intake reminders are effective in enhancing adherence to direct oral anticoagulants in stroke patients: a randomised cross-over trial (MAAESTRO study).Journal of neurology · 2024Trial
- Large Language Modeling-Enabled Analysis of Atrial Fibrillation on Social Media.Journal of the American Heart Association · 2026Article
- Medication Adherence Patterns for Patients with Atrial Fibrillation: A Mixed Methods Study to Understand Patient and Clinician Perspectives.Patient preference and adherence · 2026Article
- Adherence to oral thromboprophylaxis in atrial fibrillation: an overview for clinicians.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2025Review
- Geographic Variation in Persistence of Oral Anticoagulant Treatment Among Patients with Non-Valvular Atrial Fibrillation in the United States.Journal of clinical medicine · 2025Article
- Clinical Perspectives on Stroke Prevention in Patients with Non-valvular Atrial Fibrillation in the Philippines.Cureus · 2025Review
- Article
- Reasons for omitting anticoagulant treatment in patients with atrial fibrillation: an audit of patient records in general practice.BMC primary care · 2025Article
- Non-adherence and non-persistence of Direct Oral Anticoagulants among patients with non-valvular atrial fibrillation: a French retrospective cohort study.Scientific reports · 2025Article
- General practice-related variation in oral anticoagulant treatment of atrial fibrillation: a nationwide cohort study.BJGP open · 2025Article
- Barriers Interfere With Wide Usage of NOAC for Prevention of Thromboembolic Events Among Doctors in Sudan: A Cross-Sectional Survey February 2023.Cardiology research and practice · 2025Article
- Non-Medical Switching or Discontinuation Patterns among Patients with Non-Valvular Atrial Fibrillation Treated with Direct Oral Anticoagulants in the United States: A Claims-Based Analysis.Journal of market access & health policy · 2024Article
- Comparative Cardioprotective Effectiveness: NOACs vs. Nattokinase-Bridging Basic Research to Clinical Findings.Biomolecules · 2024Review
- Changing or Retaining Direct Oral Anticoagulant After Ischemic Stroke Despite Direct Oral Anticoagulant Treatment.Journal of the American Heart Association · 2024Article
- Assessing the impact of a financial incentive and refill reminder program on medication adherence and costs.Journal of managed care & specialty pharmacy · 2024Article
- Warfarin Adherence and Its Associated Factors in Thai Older Adults with Atrial Fibrillation.Journal of multidisciplinary healthcare · 2024Article
- Low bleeding acceptance is associated with increased death risk in patients with atrial fibrillation on oral anticoagulation.Journal of thrombosis and thrombolysis · 2024Article
- Atrial fibrillation and stroke prevention: 25 years of research at EP Europace journal.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2023Review
- Contemporary trends and barriers to oral anticoagulation therapy in Non-valvular atrial fibrillation during DOAC predominant era.International journal of cardiology. Heart & vasculature · 2023Article
- Percutaneous left atrial appendage closure: beyond the classic indications.AsiaIntervention · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atrial fibrillation (AF) is associated with an increased risk of stroke, which can be prevented by the use of oral anticoagulation. Although non-vitamin K antagonist oral anticoagulants (NOACs) have become the first choice for stroke prevention in the majority of patients with non-valvular AF, adherence and persistence to these medications remain suboptimal, which may translate into poor health outcomes and increased healthcare costs. Factors influencing adherence and persistence have been suggested to be patient-related, physician-related, and healthcare system-related. In this review, we discuss factors influencing patient adherence and persistence to NOACs and possible problem solving strategies, especially involving an integrated care management, aiming for the improvement in patient outcomes and treatment satisfaction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.